SCHEMBL6629320

SCHEMBL6629320

[CH2]C(CC(CC)C(=O)O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 5/20 0.56
SLC1A3 P43003 4/20 0.56
SLC1A1 P43005 4/20 0.56
CA2 P00918 1/20 0.46
MAPK1 P28482 1/20 0.46
CHRM1 P11229 1/20 0.42
AKR1A1 P14550 1/20 0.42
CHRM3 P20309 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GCLC P48506 2/20 0.40
GRIK1 P39086 6/20 0.38
GRIK2 Q13002 6/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751062 0.84 SLC1A2 (0.71) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL21408455 0.83 SLC1A2 (0.58) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL4856341 0.82 SLC1A2 (0.68) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL13317543 0.82 SLC1A2 (0.68) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL15217711 0.82 SLC1A2 (0.68) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL27373025 0.81 SLC1A3 (0.56) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL126993 0.76
Ethylene SCHEMBL31295702 0.76 CA2 (0.64) SLC1A2SLC1A3SLC1A1CA2MAPK1
SCHEMBL6114 0.76
SCHEMBL5970448 0.75 SLC1A2 (0.60) SLC1A2SLC1A3SLC1A1CA2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114716590-B Catalyst component for ethylene polymerization or copolymerization, preparation method and application thereof 任丘市利和科技发展有限公司 2023-11-21 CN disclosed
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed
CN-1276035-C Water-color ink MITSUI CHEMICALS INC (JP) 2006-09-20 CN disclosed
CN-1558934-A Water-color ink 三井化学株式会社 2004-12-29 CN disclosed
US-20040231558-A1 Has a clear hue, high light fastness and high moisture resistance MITSUI CHEMICALS, INC. (JP) 2004-11-25 US disclosed
EP-1441013-A1 WATERCOLOR INK Mitsui Chemicals, Inc. (JP) 2004-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 SLC1A2 2258/4885SLC1A3 1862/4885SLC1A1 1990/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 SLC1A2 2618/4885SLC1A3 2460/4885SLC1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.